Health CarePharmaceuticals & Biotechnology
  • Price (USD)12.18
  • Today's Change-0.18 / -1.46%
  • Shares traded2.49m
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Apr 03 2020 23:30 BST.
More ▼

Profile data is unavailable for this security.

About the company

Avantor, Inc. is a global provider of mission critical products and services. Its products include materials and consumables, equipment and instrumentation, and services and specialty procurement. Materials and consumables includes chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits and education and microbiology and clinical trial kits. Equipment and instrumentation includes filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets and critical environment supplies. Services and specialty procurement include onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services.

  • Revenue in USD (TTM)6.04bn
  • Net income in USD-335.10m
  • Incorporated2016
  • Employees12.00k
  • Location
    Avantor IncBuilding One100 W Matsonford Rd Ste 200RADNOR 19087United StatesUSA
  • Phone+1 (610) 386-1700
  • Fax+1 (302) 636-5454
  • Websitehttps://www.avantorsciences.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Badger Meter, Inc.424.63m47.18m1.46bn1.57k31.004.4020.433.431.611.6114.5311.371.043.216.65270,979.6011.589.0113.5311.5838.5137.7911.118.292.06245.640.013443.20-2.103.0969.769.71-9.4811.58
Fitbit Inc1.43bn-320.71m1.70bn1.68k--3.48--1.18-1.24-1.245.571.840.99517.553.38852,011.90-22.24-8.94-45.83-16.0729.8140.39-22.35-7.751.29--0.0028---5.1113.99-72.58--6.63--
Integra Lifesciences Holdings Corp1.52bn50.20m3.50bn4.00k71.422.5121.912.300.57990.579917.6216.500.47341.815.61379,389.301.572.431.732.6764.4664.883.314.971.646.020.48760.003.0613.75-17.436.7028.54--
MKS Instruments, Inc.1.90bn140.39m4.11bn5.50k29.472.0216.432.172.542.5434.4737.060.632.535.97345,413.304.6610.185.1511.3243.7145.377.3913.793.066.550.30417.81-8.4519.46-64.213.9337.124.08
Bruker Corporation2.07bn197.20m5.19bn7.23k26.695.7318.982.511.261.2613.235.880.84591.985.76286,666.708.087.9311.0211.1848.0246.449.558.781.8917.260.464313.059.342.769.7428.3116.65--
Avantor Inc6.04bn-335.10m6.98bn12.00k--4.7815.981.16-0.635-0.63510.874.300.61375.966.25503,358.300.384--0.4317--31.80--0.6258--1.221.400.6751--3.00---2.51------
Cognex Corporation725.63m203.87m7.00bn2.27k34.865.1630.629.651.,081.6012.8416.6713.7617.9773.8575.0928.1029.784.54--0.0014.27-10.0111.22-11.4812.960.7631--
Hill-Rom Holdings, Inc.2.91bn149.80m7.03bn10.00k47.334.3422.162.422.222.2243.0424.180.6565.105.14290,880.003.383.034.043.6349.3947.765.154.831.173.940.552237.192.0811.51-16.6920.067.626.88
Allegion PLC2.85bn401.80m7.78bn11.00k19.7210.2916.042.734.264.2630.268.170.9885.828.72259,454.5013.9212.3916.9515.3843.8843.6714.0912.441.4410.400.652521.394.486.14-2.7116.624.9627.54
PerkinElmer, Inc.2.88bn227.75m7.92bn13.00k34.622.8117.942.752.062.0526.0225.320.46094.284.25221,821.003.644.384.155.0848.4147.697.909.321.336.170.424313.703.805.21-3.277.1624.530.00
Bio-Rad Laboratories, Inc.2.31bn1.76bn10.94bn8.12k6.291.905.784.7358.2058.2076.81192.310.33951.855.89284,687.1025.839.8028.6811.0254.5754.7776.0820.891.80--0.0710.000.97161.23455.4681.68-4.02--
Waters Corporation2.41bn588.97m11.14bn7.50k20.59--16.064.638.748.7835.29-3.460.76593.304.16320,879.5018.7412.9522.4614.8658.0058.8724.4724.201.6826.941.150.00-0.5513.88-1.056.419.05--
Data as of Apr 03 2020. Currency figures normalised to Avantor Inc's reporting currency: US Dollar USD

Institutional shareholders

61.19%Per cent of shares held by top holders
HolderShares% Held
New Mountain Vantage Advisers LLCas of 31 Dec 2019110.48m19.28%
Goldman Sachs & Co. LLC (Private Banking)as of 31 Dec 201978.24m13.66%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 201958.86m10.27%
The Vanguard Group, Inc.as of 31 Dec 201929.47m5.14%
TIAA-CREF Investment Management LLCas of 31 Dec 201916.23m2.83%
The Public Sector Pension Investment Boardas of 31 Dec 201915.46m2.70%
American Century Investment Management, Inc.as of 31 Dec 201912.11m2.11%
Invesco Advisers, Inc.as of 31 Dec 201910.57m1.85%
BlackRock Fund Advisorsas of 31 Dec 201910.45m1.82%
Boston Partners Global Investors, Inc.as of 31 Dec 20198.72m1.52%
More ▼
Data from 31 Dec 2019 - 31 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.